The earnings call highlighted strong revenue growth and international expansion, particularly in Germany, and a record number of pipeline additions. However, the company faced challenges with lead quality and conversion, increased operating expenses, and a decrease in Medicare Advantage revenue. Myomo is making strategic adjustments to address these issues, including cost-cutting measures and shifts in advertising strategy.

Company Guidance

During the second quarter of 2025, Myomo reported revenues of $9.7 million, marking a 28% increase from the previous year, driven by a 13% rise in delivered MyoPro units and a 14% increase in average selling price (ASP) to approximately $54,200. Despite achieving a record 816 pipeline additions, the cost per pipeline add surged to approximately $2,900, up from $1,500 in recent quarters, largely due to lower lead quality. The company faced challenges in converting leads to pipeline additions and authorizations, which impacted backlog growth. The operating loss for the quarter was $4.6 million, with net loss also at $4.6 million or $0.11 per share. Myomo's gross margin decreased to 62.7% from 70.8% the prior year, primarily due to higher material costs and overhead spending. Operating expenses rose by 65% to $10.6 million, driven by increased advertising and headcount. The company anticipates third-quarter revenue to range between $9.5 million and $10 million and has revised its full-year growth expectations to 23% to 29%, projecting revenue between $40 million and $42 million for 2025.

Revenue Growth and International Expansion

Myomo's revenue for Q2 2025 was $9.7 million, representing a 28% increase year-over-year. International revenue, primarily from Germany, was $1.5 million, up 41% year-over-year, showcasing significant growth in that segment.

Record Pipeline Additions

The company added a record 816 patients to the pipeline in Q2, up 49% over the prior year quarter, reflecting successful lead generation efforts.

Rising Average Selling Price

The average selling price (ASP) of MyoPro units increased by 14% compared to the prior year, reaching approximately $54,200.

Operational Efficiency and Cost Management

Myomo undertook a 8% headcount reduction in the U.S. and cut back on outside services spending, expected to save at least $2 million over the next 12 months.

Myomo (MYO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MYO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.09 / -	-0.03	―	―	―
Aug 11, 2025	2025 (Q2)	-0.11 / -0.11	-0.03	-266.67% (-0.08)	―
May 07, 2025	2025 (Q1)	-0.08 / -0.08	-0.1	20.00% (+0.02)	―
Mar 10, 2025	2024 (Q4)	-0.02 / -0.01	-0.07	85.71% (+0.06)	―
Nov 06, 2024	2024 (Q3)	-0.04 / -0.03	-0.06	50.00% (+0.03)	―
Aug 06, 2024	2024 (Q2)	-0.07 / -0.03	-0.04	25.00% (+0.01)
May 08, 2024	2024 (Q1)	-0.10 / -0.10	-0.11	9.09% (<+0.01)
Mar 07, 2024	2023 (Q4)	-0.06 / -0.07	-0.29	75.86% (+0.22)	―
Nov 07, 2023	2023 (Q3)	-0.09 / -0.06	-0.4	85.00% (+0.34)	―
Aug 09, 2023	2023 (Q2)	-0.03 / -0.04	-0.42	90.48% (+0.38)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MYO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$1.76	$1.08	-38.64%
May 07, 2025	$4.84	$3.36	-30.58%
Mar 10, 2025	$4.17	$5.87	+40.77%
Nov 06, 2024	$4.18	$5.02	+20.10%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.